Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals.

Experts said that the novel combination of a GLP-1 and amylin analogue will help obese patients with and without diabetes ...

The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared with placebo in patients with overweight or obesity with or without ...

CNW/ – This week, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3 REDEFINE 1 trial ...

A NEW Phase 3 trial has shown that a combination therapy of cagrilintide and semaglutide (CagriSema) can lead to substantial ...

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...

CagriSema expected to yield more weight loss Novo Nordisk's head of development, Martin Holst Lange, told Reuters that CagriSema could deliver 25 percent weight loss, compared to Wegovy's 15 percent.

Additionally, a supportive secondary analysis showed that 50.7% of participants with obesity treated with CagriSema reached non-obesity levels (BMI 30 kg/m²) by the end of treatment, down from a mean ...

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, Novo Nordisk pointed to a good tolerability profile for CagriSema and ...

CagriSema, which includes a nascent form of weight loss treatment known as an amylin analog, is one of the Danish pharma's next bets on the burgeoning obesity market.

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late ...

Walmart has agreed to pay $10 million to settle a U.S. Federal Trade Commission civil lawsuit accusing the world's largest ...